> If it's so easy to fix the system, people would have already done it.
This doesn't follow at all. The difficulty of fixing a system is just one possible reason it might remain as it does; regulatory capture is another, as is well-financed lobbying at the legislative level.
Pharmaceutical companies have a very clear financial interest in seeing as broad as possible use of their products, and demonstrably have the lobbying reach to forcefully advance this interest. If reform of medical trial data regulation is not a vote-winning platform (and it's hard to argue that it's uppermost in many voters' minds), then it's perfectly plausible that a broken system would persist despite the availability of easily-implemented solutions.
You are proving my point. There are many difficulties to fixing the system. Broken system persists because 'solutions' cannot be easily/successfully implemented.
This doesn't follow at all. The difficulty of fixing a system is just one possible reason it might remain as it does; regulatory capture is another, as is well-financed lobbying at the legislative level.
Pharmaceutical companies have a very clear financial interest in seeing as broad as possible use of their products, and demonstrably have the lobbying reach to forcefully advance this interest. If reform of medical trial data regulation is not a vote-winning platform (and it's hard to argue that it's uppermost in many voters' minds), then it's perfectly plausible that a broken system would persist despite the availability of easily-implemented solutions.